Press Room

RDD 2016

Start
Sunday, April 17, 2016 - 00:00
End
Thursday, April 21, 2016 - 23:45
Location: Arizona, USA
Booth Number: 14

The Respiratory Drug Delivery (RDD®) 2016 will be held at the Westin Kierland Resort, Phoenix, Arizona, April 17-21, 2016.

Hovione will be present with a table and a set of posters.

 

HOVIONE'S POSTERS

Particle Engineered Glycopyrrolate Inhalation Grade: A Comprehensive Solid State Characterization Study
Susana Campos

From TwinCaps® to TwinMax™: Optimizing a Disposable Inhaler for High Dosage Applications Through CFD
João Fernandes

Impact of the API Concentration on the Solid State Properties and Aerodynamic Performance of Composite Particles for DPIs
Diana Fernandes

Strategies to Deliver Doxycycline Monohydrate via Inhalation
Maria Palha

Alternatives to Lactose-only Carrier-based Formulations: The Use of Mannitol and Magnesium Stearate
Bruno Santos

Using Laser Diffraction for the Advanced Characterization of Nebulization Products - Part 1: Discriminative Power via Standard Data Analysis
Isabel Sequeira Lopes

Using Laser Diffraction for the Advanced Characterization of Nebulization Products - Part 2: Extended Data Analysis and Correlation with Cascade Impaction
Isabel Sequeira Lopes

Dry Powder Inhalers Characterization: Comparison Between Full and Abbreviated Impactor Testing
Sofia Silva

 

Details about the event
To find more about the posters, contact us

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026